טוען...
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy
PURPOSE: Antiangiogenic therapy is commonly being used for the treatment of glioblastoma. However, the benefits of angiogenesis inhibitors are typically transient and resistance often develops. Determining the mechanism of treatment failure of the VEGF monoclonal antibody bevacizumab for malignant g...
שמור ב:
הוצא לאור ב: | Oncotarget |
---|---|
Main Authors: | , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Impact Journals LLC
2015
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4741619/ https://ncbi.nlm.nih.gov/pubmed/26362401 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|